JP2020519669A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519669A5
JP2020519669A5 JP2019563191A JP2019563191A JP2020519669A5 JP 2020519669 A5 JP2020519669 A5 JP 2020519669A5 JP 2019563191 A JP2019563191 A JP 2019563191A JP 2019563191 A JP2019563191 A JP 2019563191A JP 2020519669 A5 JP2020519669 A5 JP 2020519669A5
Authority
JP
Japan
Prior art keywords
pellet according
ethyl cellulose
weight
release coating
hpmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033205 external-priority patent/WO2018213589A1/en
Publication of JP2020519669A publication Critical patent/JP2020519669A/ja
Publication of JP2020519669A5 publication Critical patent/JP2020519669A5/ja
Priority to JP2023073242A priority Critical patent/JP7499539B2/ja
Pending legal-status Critical Current

Links

JP2019563191A 2017-05-17 2018-05-17 ホモタウリンおよびその塩の製剤 Pending JP2020519669A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023073242A JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507532P 2017-05-17 2017-05-17
US62/507,532 2017-05-17
US201862660690P 2018-04-20 2018-04-20
US62/660,690 2018-04-20
PCT/US2018/033205 WO2018213589A1 (en) 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023073242A Division JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Publications (2)

Publication Number Publication Date
JP2020519669A JP2020519669A (ja) 2020-07-02
JP2020519669A5 true JP2020519669A5 (cg-RX-API-DMAC7.html) 2021-07-26

Family

ID=64274653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563191A Pending JP2020519669A (ja) 2017-05-17 2018-05-17 ホモタウリンおよびその塩の製剤
JP2023073242A Active JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023073242A Active JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Country Status (8)

Country Link
US (1) US12042566B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624788A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020519669A (cg-RX-API-DMAC7.html)
KR (1) KR20200005576A (cg-RX-API-DMAC7.html)
AU (2) AU2018269557B2 (cg-RX-API-DMAC7.html)
IL (1) IL270654B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018213589A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201908264B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURIN AND SALT THEREOF
WO2025163673A1 (en) * 2024-01-29 2025-08-07 Micro Labs Limited Dose-dumping resistant tablets of acamprosate calcium

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01280192A (ja) 1988-10-25 1989-11-10 Nichibei Co Ltd ブラインド内装サッシ
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
RU2375048C2 (ru) 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CA2504471A1 (en) * 2004-06-18 2005-12-18 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
WO2009004082A2 (en) 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
ES2530047T3 (es) 2009-02-12 2015-02-26 Indiana University Research And Technology Corporation Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9195775B2 (en) 2009-06-26 2015-11-24 Iii Holdings 2, Llc System and method for managing and/or rendering internet multimedia content in a network
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US9000046B2 (en) * 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
RS53227B (sr) * 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
WO2012129551A1 (en) * 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
WO2013002584A2 (ko) 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
AU2012345659B2 (en) * 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
RU2675252C2 (ru) 2012-07-22 2018-12-18 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн МОДУЛЯЦИЯ УРОВНЕЙ sAPP, sAPPα И BDNF У ИНДИВИДУУМОВ С ДИАГНОЗОМ FXS И ASD
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3104850A1 (en) * 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
KR102790656B1 (ko) 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
AU2016303610A1 (en) 2015-08-04 2018-02-01 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and D-cycloserine
JP6066009B1 (ja) 2016-06-16 2017-01-25 富士電機株式会社 ガス絶縁開閉装置用操作器及びそれを用いたガス絶縁開閉装置
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURIN AND SALT THEREOF

Similar Documents

Publication Publication Date Title
JP2019147832A5 (cg-RX-API-DMAC7.html)
JP2009502487A5 (cg-RX-API-DMAC7.html)
JP2009545560A5 (cg-RX-API-DMAC7.html)
JP2012236837A5 (cg-RX-API-DMAC7.html)
JP2019513800A5 (cg-RX-API-DMAC7.html)
JP2010511663A5 (cg-RX-API-DMAC7.html)
KR20110081316A (ko) 디아세레인 함유 약제학적 조성물
JP2012153724A5 (cg-RX-API-DMAC7.html)
JP2014523445A5 (cg-RX-API-DMAC7.html)
RU2014101227A (ru) Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм
CA2651716A1 (en) Duloxetine hydrochloride delayed release formulations
CN101431986A (zh) 固体剂型调配物
CN103784414B (zh) 一种埃索美拉唑肠溶片及其制备方法
US20140178468A1 (en) Multiparticulate extended-release composition of mesalamine
US20090004284A1 (en) Controlled release tamsulosin hydrochloride formulation
US20110052687A1 (en) Extended release pharmaceutical composition of paliperidone
JP2024506595A5 (cg-RX-API-DMAC7.html)
RU2008136766A (ru) Таблетки метопролола сукцината пролонгированного действия и способы их приготовления
RU2016102605A (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
RU2015138784A (ru) Фармацевтическая композиция в виде мультичастиц, содержащая множество гранул двух видов
CN101721385B (zh) 一种美沙拉嗪口服控释药物组合物
WO2014060561A1 (en) Oral pharmaceutical formulations comprising dabigatran
JP2024040951A5 (cg-RX-API-DMAC7.html)
ITFI20100175A1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
US20100172972A1 (en) Enteric coated pharmaceutical compositions